. High unmet medical need
. Rapid market entry
Endotis develops innovative products based on validated targets and compounds that have been successfully marketed. Therefore, the risk and the timelines associated with their development are considerably lower than that of traditional new molecular entities (NMEs)
Today, coronary artery bypass grafts (CABG) and valve replacements are associated with significant clinical complications, including mortality, major bleeding and re-operation, massive transfusions, myocardial infarction and stroke. The management of extra corporeal circulation during cardiac surgery must, at the same time, minimize the risk of clotting in the machine's tubing and the risk of bleeding from using very high doses of anticoagulant. The only option currently used is un-fractionated heparin, a product that has a short half-life, is unpredictable, difficult to manage and has many undesirable side-effects. With a stable and predictable PK/PD profile, Endotis' lead product is projected to significantly improve the safety and effectiveness of anticoagulation during cardiopulmonary bypass
Similarly, the development of an oral form of fondaparinux is expected to answer clinicians' expressed interest in prescribing fondaparinux "pills" rather than syringes for the mid- to long-term prevention of venous thromboembolism
The Company's clinical development programs are shorter and cheaper than conventional cardiovascular products due to the nature of the target populations, the projected benefits and/or established market presence. Market launches are projected beginning in 2015
